- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04364685
Effect of Walking on Sand With Dietary Intervention in Overweight Type 2 Diabetes Mellitus Patients.
Effect of Walking on Sand With Dietary Intervention in Overweight Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial.
Type 2 Diabetes Meletus(T2DM) is a global health concern. The incidence of T2DM globally is increasing exponentially partly due to unhealthy food habits and sedentary life style.exercise and nutritional intervention is long being reported to improve glycemic control and improve quality of life among individuals with T2DM.
Moderate intensity of walking for 30 minutes is proven to regulate good metabolic control. however, in over weight elderly individuals, joint pain or arthritis walking be a challenging task. therefore, walking on sand which is reported to be easy on joints would be a alternative for those patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Riyadh
-
Al Majma'ah, Riyadh, Saudi Arabia, 11952
- King Khalid Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes for past 1 year.
- HbA1c between 7-10%.
- BMI between 25-29.9
- Age Between 45-75
- Sedentary
Exclusion Criteria:
- Diabetic Neuropathy
- Active Smoker
- Musculoskeletal conditions
- Cardiovascular conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Normal Walking
The participants performed 30 minutes on levelled surface on the track and field ground.
Participants performed moderate intensity walking, self paced.
|
The Participants will be require to walk on the firm surface for 30 minutes.
The participants would decide the pace of walking.
|
Experimental: Sand Walking
The participants performed supervised walking on sand on the 20 meters pathway containing soft sand.The walking on sand for 30 minutes.
|
The participants are required to walking on sand for 30 minutes.
Walking is self-paced.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: 16 weeks
|
Percentage of hemoglobin A1c
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMI
Time Frame: 16 weeks
|
Body mass index
|
16 weeks
|
Waist Circumference
Time Frame: 2 years
|
the waist circumference was measured by inch tape at the level of Anterior superior iliac spine.
|
2 years
|
Quality of life-39
Time Frame: 16 weeks
|
The Validated quality of life for diabetes containing 39 items and scoring on a 1-7 Likert scale.
|
16 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MajmaahUNI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Walking on Levelled Surface
-
Nantes University HospitalCompleted
-
Khon Kaen UniversityCompleted
-
Universidade Cruzeiro do SulCompleted
-
Hangzhou Yirui Pharmaceutical Technology Co., LtdCompletedPsoriasis | Atopic DermatitisUnited States
-
Majmaah UniversityUnknownChronic StrokeSaudi Arabia
-
Marmara UniversityNot yet recruiting
-
University of Nevada, Las VegasRecruitingAmputationUnited States
-
University Hospital, GhentUniversity GhentRecruiting
-
Eleftheria GiannouliRecruiting
-
Rutgers, The State University of New JerseyTerminated